Spots Global Cancer Trial Database for dlbcl
Every month we try and update this database with for dlbcl cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Safety Study of SGN-35T in Adults With Advanced Cancers | NCT06120504 | Lymphoma, T-Cel... Hodgkin Disease Lymphoma, T-Cel... Lymphoma, Large... Lymphoma, Large... Lymphoma, Non-H... | SGN-35T | 18 Years - | Seagen Inc. | |
| Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL. | NCT00355199 | Diffuse Large B... | Rituximab-HDS Rituximab-CHOP | 18 Years - 65 Years | Gruppo Italiano Terapie Innovative nei Linfomi | |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | NCT02440685 | Lymphoma, Large... Lymphoma, Mantl... Lymphoma, Folli... Cancer Neoplasm Tumor Lymphoma, Malig... Lymphoma, B-cel... Lymphoma, Non-H... B-Cell Chronic ... B-Cell Leukemia... B-Lymphocytic L... Chronic Lymphoc... Leukemia, Lymph... Leukemia, Lymph... Myelofibrosis Chronic Idiopat... Idiopathic Myel... Lymphoma, T Cel... Peripheral T-Ce... T-Cell Lymphoma... | ASN002 Dose Esc... ASN002 RD | 18 Years - | Asana BioSciences | |
| Safety and Efficacy of Entospletinib (ENTO [GS-9973]) Combined With Vincristine (VCR) in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NHL) | NCT02568683 | Non-Hodgkin Lym... | Entospletinib Vincristine | 18 Years - | Gilead Sciences | |
| R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL | NCT01148446 | Elderly Patient... Diffuse Large B... | Cyclophosphamid... Cyclophosphamid... Doxorubicin Vincristine Prednisone Prednisone Epirubicin Vinblastine Rituximab G-CSF | 66 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Maintenance Hormonal Therapy and DLBCL | NCT06355401 | Diffuse Large B... | Tamoxifen 20mg | 18 Years - 75 Years | Sohag University | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients | NCT03364439 | Diffuse Large B... | Treatment plan | 18 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| A Study Comparing the Efficacy and Safety Between H-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | NCT05040906 | Recruiting | H02+CHOP Rituxan +CHOP | 18 Years - 75 Years | Shandong New Time Pharmaceutical Co., LTD | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma | NCT03758989 | DLBCL | Rituximab Predn... Cyclophosphamid... Doxorubicin Vincristine Prednisone | 18 Years - | University of Rochester | |
| A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02532192 | Lymphoma | Belinostat Rituximab Cisplatin Cytarabine Dexamethasone Ciprofloxacin Fluconazole | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| A Multiple Ascending Dose Study of MEDI7247 in Patients With Selected Relapsed/Refractory Hematological Malignancies | NCT03106428 | Acute Myeloid L... Multiple Myelom... Diffuse Large B... | MEDI7247 | 18 Years - 100 Years | MedImmune LLC | |
| A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas | NCT03575351 | Lymphoma, Non-H... | Standard of Car... JCAR017 | 18 Years - 75 Years | Celgene | |
| Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment | NCT00324467 | Lymphoma, Non-H... Advanced Stage ... | Cyclophosphamid... Doxorubicin Vincristine Prednisone Ondansetron Dexamethasone Diphenhydramine Acetaminophen Ifosfamide Mesna (IV) Mesna (oral) Carboplatin Etoposide Rituximab Ondansetron Dexamethasone Diphenhydramine Acetaminophen PET Scan | 18 Years - | British Columbia Cancer Agency | |
| Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma | NCT01361191 | Diffuse Large B... Follicular Grad... | R-MEGACHOP | 18 Years - 65 Years | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | |
| Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma | NCT05412290 | B Cell Lymphoma Aggressive Lymp... Diffuse Large B... High-grade B-ce... Transformed Lym... Follicular Lymp... | Mosunetuzumab | 18 Years - | Washington University School of Medicine | |
| GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | NCT01659099 | Diffuse Large B... | GA101 Rituximab Doxorubicin Cyclophosphamid... Prednisone Bleomycin Vindesin Vincristine | 18 Years - 60 Years | The Lymphoma Academic Research Organisation | |
| SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers? | NCT03672682 | DLBCL | 18 Years - 70 Years | Rennes University Hospital | ||
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228 | NCT05737628 | Lymphoma | BYON4228 + Ritu... | 18 Years - | Byondis B.V. | |
| Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04) | NCT01502982 | Diffuse Large B... | R-CHOEP14x6+HD-... | 18 Years - 64 Years | Nordic Lymphoma Group | |
| Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | NCT01499303 | Diffuse Large B... | Fostamatinib | 18 Years - | AstraZeneca | |
| A Study of AZD0486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NCT04594642 | B-cell Non Hodg... Diffuse Large B... High-grade B-ce... Follicular Lymp... | AZD0486 IV | 18 Years - 130 Years | AstraZeneca | |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma | NCT04433182 | Diffuse Large B... | Copanlisib | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma | NCT00869999 | Diffuse Large B... | Everolimus rituximab | 18 Years - | Massachusetts General Hospital | |
| Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL | NCT03795571 | Diffuse Large B... Diffuse Large B... | Rituximab Gemcitabine Oxaliplatin Dexamethasone Lenalidomide Or... | 18 Years - 65 Years | The First Affiliated Hospital with Nanjing Medical University | |
| Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | NCT02992483 | Multiple Myelom... | MIK665 | 18 Years - | Novartis | |
| Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL | NCT05863845 | Diffuse Large B... | Venetoclax Carmustine Cytarabine Etoposide Melphalan Hematopoietic C... | 18 Years - 65 Years | Ruijin Hospital | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma | NCT05757700 | B-Cell Lymphoma Large B-cell Ly... DLBCL, Nos Gene... High-grade B Ce... Mediastinal Lar... | 19(T2)28z1xx TR... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse | NCT03356054 | DLBCL | R-DHAP Brentuximab Ved... | 18 Years - | Stichting Hemato-Oncologie voor Volwassenen Nederland | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT00776802 | Diffuse Large B... | GCS-100 Etoposide; Dexa... | 18 Years - | La Jolla Pharmaceutical Company | |
| Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma | NCT00445341 | Lymphoma | Flavopiridol | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma | NCT02934204 | Primary CNS Lym... | methotrexate temozolomide | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| GA In NEwly Diagnosed Diffuse Large B Cell Lymphoma | NCT01659099 | Diffuse Large B... | GA101 Rituximab Doxorubicin Cyclophosphamid... Prednisone Bleomycin Vindesin Vincristine | 18 Years - 60 Years | The Lymphoma Academic Research Organisation | |
| Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | NCT04824092 | Diffuse Large B... | Tafasitamab Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Tafasitamab pla... Lenalidomide pl... | 18 Years - 80 Years | MorphoSys AG | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma | NCT04082936 | Non-Hodgkin Lym... Follicular Lymp... DLBCL Mantle Cell Lym... Marginal Zone L... | imvotamab | 18 Years - | IGM Biosciences, Inc. | |
| Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte Malignancies | NCT05541341 | Diffuse Large B... Acute Lymphobla... Follicular Lymp... | tisagenlecleuce... | - 100 Years | Novartis | |
| Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL | NCT05093140 | Primary Extrano... DLBCL | Camrelizumab | 18 Years - 65 Years | Sun Yat-sen University | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients. | NCT02670317 | Lymphoma, B-Cel... | Obinutuzumab Ibrutinib CHOP | 18 Years - 60 Years | Fondazione Italiana Linfomi - ETS | |
| KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma | NCT02471911 | Diffuse Large B... | KPT-330 Rituximab Etoposide Carboplatin Ifosfamide Dexamethasone | 18 Years - | Weill Medical College of Cornell University | |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma | NCT05381506 | DLBCL | Orelabrutinib a... | 18 Years - | Sun Yat-sen University | |
| Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma | NCT02934204 | Primary CNS Lym... | methotrexate temozolomide | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| Phase I Study of MIK665, a Mcl-1 Inhibitor, in Patients With Refractory or Relapsed Lymphoma or Multiple Myeloma | NCT02992483 | Multiple Myelom... | MIK665 | 18 Years - | Novartis | |
| Real-World Study of DLBCL With Different Genetic Subtypes | NCT06026488 | DLBCL - Diffuse... Lymphoma | Other | 18 Years - | Ruijin Hospital | |
| A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma | NCT03688152 | Relapsed Diffus... Refractory Diff... | INCB053914 INCB050465 | 18 Years - | Incyte Corporation | |
| Evaluation of CAR19 T-cells as an Optimal Bridge to Allogeneic Transplantation | NCT02431988 | Diffuse Large B... | Leukapheresis Cyclophosphamid... Fludarabine CAR19 T-Cells | 16 Years - 65 Years | University College, London | |
| Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression | NCT06005870 | Diffuse Large B... | Zanubrutinib pl... | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | NCT02077166 | Relapsed Diffus... Refractory Diff... | Ibrutinib Lenalidomide Rituximab | 18 Years - | Pharmacyclics LLC. | |
| Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies | NCT01760226 | Diffuse Large B... Post Transplant... Primary Mediast... | DA-EPOCH-R for ... Methotrexate Etoposide Doxorubicin Vincristine Rituximab Cyclophosphamid... Prednisone G-CSF | - 30 Years | Baylor College of Medicine | |
| Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | NCT01938638 | Neoplasms | BAY1143572 | 21 Years - | Bayer | |
| PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | NCT03120000 | Primary Central... | PQR309 | 18 Years - | PIQUR Therapeutics AG | |
| A Phase II Study of Oral Panobinostat (LBH589) and Rituximab to Treat Diffuse Large B Cell Lymphoma (DLBCL) | NCT01238692 | Diffuse Large B... | LBH589 Rituximab | 18 Years - | Jewish General Hospital | |
| Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05) | NCT02658968 | Relapsed, Diffu... Refractory Diff... | Betalutin | 18 Years - | Nordic Nanovector | |
| Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | NCT02142530 | Non-Hodgkin Lym... Diffuse Large B... Mantle Cell Lym... Follicular Lymp... Peripheral T-ce... | Carfilzomib Belinostat | 18 Years - | Massachusetts General Hospital | |
| A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas | NCT05934838 | Follicular Lymp... B-Cell Lymphoma Mantle Cell Lym... Diffuse Large B... | Tazemetostat Pi... | 18 Years - | Weill Medical College of Cornell University | |
| Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas | NCT02503423 | Solid Tumors Lymphoma | ASTX660 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL | NCT02141451 | Diffuse Large B... | Rituximab INCB7839 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients | NCT03364439 | Diffuse Large B... | Treatment plan | 18 Years - 80 Years | Fondazione Italiana Linfomi - ETS | |
| Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas | NCT03985696 | Lymphoma, B-cel... | blood sample | 18 Years - | University Hospital, Limoges | |
| Dose-adjusted EPOCH-R in MYC Positive DLBCL | NCT01914718 | Diffuse Large B... | DA-EPOCH-R | 18 Years - 70 Years | Fudan University | |
| Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma | NCT05326243 | Diffuse Large B... Primary Mediast... Large B-cell Ly... Follicular Lymp... Follicular Lymp... | CD19-targeted c... | 14 Years - 70 Years | Pell Bio-Med Technology Co., Ltd. | |
| Split-Dose R-CHOP for Older Adults With DLBCL | NCT03943901 | Diffuse Large B... DLBCL Cancer | Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone Pegfilgrastim | 70 Years - | University of Wisconsin, Madison | |
| Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer | NCT01499303 | Diffuse Large B... | Fostamatinib | 18 Years - | AstraZeneca | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| Dose-adjusted EPOCH-R in MYC Positive DLBCL | NCT01914718 | Diffuse Large B... | DA-EPOCH-R | 18 Years - 70 Years | Fudan University | |
| Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies | NCT01796470 | Chronic Lymphoc... Mantle Cell Lym... Diffuse Large B... Indolent Non-Ho... | Entospletinib Idelalisib | 18 Years - | Gilead Sciences | |
| CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma | NCT03287817 | Diffuse Large B... Relapsed Diffus... Refractory Diff... DLBCL | AUTO3 | 18 Years - | Autolus Limited | |
| A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated | NCT03888105 | B-cell Non-Hodg... | Odronextamab | 18 Years - | Regeneron Pharmaceuticals | |
| Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy | NCT00790036 | Diffuse Large B... | Everolimus Everolimus Plac... | 18 Years - | Novartis | |
| Diet, Physical Activity and Body Composition Changes During R-CHOP | NCT04293900 | Non-Hodgkin Lym... DLBCL Diffuse Large B... | 24-hour dietary... Hand grip stren... International P... Patient-reporte... Pittsburgh Slee... Functional Asse... urine sample (o... fecal sample (o... | 18 Years - | George Washington University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
